Pharma redoubles effort against 10 neglected tropical diseases

19 April 2017
mosquito_big

A group of major pharmaceutical companies are carrying out a commitment to control or eliminate the 10 neglected tropical diseases (NTD) responsible for 90% of the global NTD burden.

The goal is part of the London Declaration, a coordinated effort by more than 20 major pharmaceutical companies and non-profit bodies to combat diseases affecting up to 1.5 billion people, primarily in developing countries.

Six of those companies are now working with charitable research group Drugs for Neglected Diseases initiative (DNDi), in a new collaboration to make good on that promise.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical